Glucagon-Like Peptide-1 Receptor
-
Subject Areas on Research
-
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
-
Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake.
-
Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population".
-
Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
-
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
-
Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.
-
CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors.
-
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
-
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.
-
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
-
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
-
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
-
Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats.
-
Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem.
-
Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
-
Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence.
-
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
-
Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.
-
DREADDing proglucagon neurons: a fresh look at metabolic regulation by the brain.
-
Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia.
-
Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
-
Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells.
-
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
-
Disruption of Glucagon-Like Peptide 1 Signaling in Sim1 Neurons Reduces Physiological and Behavioral Reactivity to Acute and Chronic Stress.
-
Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism.
-
Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
-
Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
-
Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.
-
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
-
Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
-
Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor.
-
Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.
-
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
-
Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.
-
GLP-1 Receptor Blockade Reduces Stimulated Insulin Secretion in Fasted Subjects With Low Circulating GLP-1.
-
GLP-1 and energy balance: an integrated model of short-term and long-term control.
-
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
-
GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats.
-
GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats.
-
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs.
-
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
-
Genetically Encoded Cholesterol-Modified Polypeptides.
-
Give the receptor a brake: slowing gastric emptying by GLP-1.
-
Glucagon lowers glycemia when β-cells are active.
-
Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
-
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
-
Glucagon-like peptide 1 (GLP-1).
-
Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic.
-
Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
-
Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.
-
Gut peptides in the treatment of diabetes mellitus.
-
High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
-
Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus.
-
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
-
Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin.
-
Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans.
-
Is GLP-1 a hormone: Whether and When?
-
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk.
-
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
-
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
-
Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility.
-
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
-
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
-
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
-
Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.
-
New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
-
Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
-
Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice.
-
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
-
Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
-
Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
-
Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss.
-
Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.
-
Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
-
Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia.
-
Targeted gene disruption in endocrine research--the case of glucagon-like peptide-1 and neuroendocrine function.
-
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
-
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
-
The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice.
-
The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness.
-
The effects of GLP-1 infusion in the hepatic portal region on food intake.
-
The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis.
-
The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.
-
The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride.
-
The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs.
-
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue.
-
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
-
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
-
Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.
-
What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract.